1.95Open1.95Pre Close0 Volume0 Open Interest6.00Strike Price0.00Turnover132.61%IV1.70%PremiumDec 20, 2024Expiry Date1.88Intrinsic Value100Multiplier19DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type-0.8590Delta0.1820Gamma2.11Leverage Ratio-0.0067Theta-0.0022Rho-1.81Eff Leverage0.0021Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet